Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 9, 2020
Daily News
April 9, 2020
- Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
- Chuikyo Allows Round Robin Meetings for Coronavirus-Related Matters
April 9, 2020
- Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
April 9, 2020
- PMDA to Accept Trial Notifications by Email amid Coronavirus Outbreak
April 9, 2020
- MHLW Staffer Infected with Novel Coronavirus
April 9, 2020
- Talks with Regulators Ongoing for Ferinject, Zeria Says after Skipping Listing 4 Times
April 9, 2020
- MSD Introduces AI Chatbot for Information Provisioning of Keytruda
April 9, 2020
- FunPep Joins AnGes, Osaka Univ. Partnership to Develop Novel Coronavirus Vaccine
April 9, 2020
- AMED Invites Research Projects for COVID-19 Vaccine Development from Mid-April
April 9, 2020
- Chugai to Launch Actemra PIII Trial for Coronavirus
April 9, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…